Literature DB >> 20663759

A case of insufficient evidence equipoise: the NICE guidance on antibiotic prophylaxis for the prevention of infective endocarditis.

R K Mohindra1.   

Abstract

This paper argues that the National Institute for Health and Clinical Excellence should not offer guidance in situations where there is insufficient evidence equipoise about the potential benefit of the treatment in question. This is broadly for two reasons. First, without knowing if the treatment is effective no cost-effectiveness judgement can be logically made. Second, the implementation of a population wide change in treatment where there is equipoise amounts to a de facto clinical trial that falls outside the Clinical Trials Regulations. As such there are strong ethical and possibly legal grounds for preventing such an outcome. Guidance based upon insufficient evidence equipoise also impacts upon the clinical discretion possessed by individual medical professionals.

Entities:  

Mesh:

Year:  2010        PMID: 20663759     DOI: 10.1136/jme.2010.036848

Source DB:  PubMed          Journal:  J Med Ethics        ISSN: 0306-6800            Impact factor:   2.903


  4 in total

Review 1.  Antibiotic prophylaxis for dental procedures.

Authors:  Christopher G Daly
Journal:  Aust Prescr       Date:  2017-10-03

Review 2.  Infective endocarditis prophylaxis: moving from dental prophylaxis to global prevention?

Authors:  C Chirouze; B Hoen; X Duval
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-02-23       Impact factor: 3.267

3.  Guidelines on prophylaxis to prevent infective endocarditis.

Authors:  M H Thornhill; M Dayer; P B Lockhart; M McGurk; D Shanson; B Prendergast; J B Chambers
Journal:  Br Dent J       Date:  2016-01-22       Impact factor: 1.626

Review 4.  Mechanisms of infective endocarditis: pathogen-host interaction and risk states.

Authors:  Karl Werdan; Sebastian Dietz; Bettina Löffler; Silke Niemann; Hasan Bushnaq; Rolf-Edgar Silber; Georg Peters; Ursula Müller-Werdan
Journal:  Nat Rev Cardiol       Date:  2013-11-19       Impact factor: 32.419

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.